SEC Form 4 · accession 0001638599-15-000230
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brent L Larson
Officer — EVP, CFO, Treas & Sec'y
Period of report
Oct 1, 2015
Accepted (ET)
Oct 5, 2015 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 1, 2015 | S | 12,500 | $2.27 | D | 247,237 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sales effected pursuant to a 10b5-1 trading plan adopted by Mr. Larson on March 13, 2015.
- F2Weighted average of sales prices ranging from $2.21 to $2.35 per share. Mr. Larson undertakes to provide upon request by the Staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.